Next Article in Journal
Microwave-Assisted and Green Fabrication of Carbon Quantum Dots from Viburnum opulus for Potential Bioimaging Applications
Previous Article in Journal
Autocrine Growth Hormone (GH)-Mediated Triptolide Resistance Overcame by Metformin Co-Treatment in MDA-MB231 Breast Cancer Cells Through ER Stress Pathway
Abstract

Epibrassinolide Promotes the Apoptotic Potential of Gemcitabine in Pancreatic Cancer Cells

Dept. of Molecular Biology and Genetics, Istanbul Kultur University, Atakoy Campus, 34156 Istanbul, Turkey
*
Author to whom correspondence should be addressed.
Presented at the 3rd International conference on Natural Products for Cancer Prevention and Therapy, Kayseri, Turkey, 18–20 December 2019.
Proceedings 2019, 40(1), 10; https://doi.org/10.3390/proceedings2019040010
Published: 25 December 2019
Pancreatic cancer is a lethal disease for which the incidence and mortality rates are close. Patients with advanced stage have median survival of three months. Gemcitabine (GEM), the anticancer analog of deoxycytidine, has been considered standard care of pancreatic cancer. However, disease progression usually occurs. Despite the effort for better treatment options, phase trials fail due to severe side effects. Epibrassinolid (EBR) is a member of brassinnosteroids with similar chemical structure to steroid hormones. Our group showed that EBR induces apoptosis via endoplasmic reticulum stress induction both in in vitro and in vivo cancer models, without effecting non-cancerous cells or non-tumor bearing mouse. Our aim in this study is to evaluate whether EBR has the potential to increase the apoptotic effect of GEM in AsPc1 pancreatic cells. We showed by MTT assay that EBR has apoptotic efficiency in AsPc1 cells and it also increases the cell viability loss when combined with GEM. The combination of EBR (30 µM) and GEM (100 µM) further increases mitochondrial membrane potential loss and nuclear condensation. In addition, exposure of cells to EBR and GEM co-treatment induces subG1 apoptotic population showed by FACS flow analysis. Consequently, we suggest that the effect of GEM can be increased with EBR combination.
Keywords: pancreatic cancer; epibrassinolide; gemcitabine; apoptosis pancreatic cancer; epibrassinolide; gemcitabine; apoptosis
MDPI and ACS Style

Kuryayeva, F.; Arisan, E.D.; Gurkan, A.C.; Yerlikaya, P.O. Epibrassinolide Promotes the Apoptotic Potential of Gemcitabine in Pancreatic Cancer Cells. Proceedings 2019, 40, 10. https://doi.org/10.3390/proceedings2019040010

AMA Style

Kuryayeva F, Arisan ED, Gurkan AC, Yerlikaya PO. Epibrassinolide Promotes the Apoptotic Potential of Gemcitabine in Pancreatic Cancer Cells. Proceedings. 2019; 40(1):10. https://doi.org/10.3390/proceedings2019040010

Chicago/Turabian Style

Kuryayeva, Fadina, Elif Damla Arisan, Ajda Coker Gurkan, and Pınar Obakan Yerlikaya. 2019. "Epibrassinolide Promotes the Apoptotic Potential of Gemcitabine in Pancreatic Cancer Cells" Proceedings 40, no. 1: 10. https://doi.org/10.3390/proceedings2019040010

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop